⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of IBM and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
IBM
↗Armonk, New York, United States
IBM is a global multinational technology and consulting company providing cloud computing, AI, quantum computing, and enterprise software solutions. While IBM is not a pharmaceutical manufacturer, the company plays a significant role in the pharma industry through its technology platforms, consulting services, and AI/quantum drug discovery initiatives. IBM provides high-security cloud infrastructure, domain-specific AI solutions through its watsonx platform, quantum computing capabilities for drug development, and comprehensive consulting services to pharmaceutical and biotech companies. The company has pivoted from its earlier Watson for Drug Discovery program (discontinued in 2019) to focus on generative AI, foundation models, and quantum computing for therapeutic development, partnering with major pharma players like Boehringer Ingelheim and Moderna.
CLASSIFICATION
Company Type:-
Therapeutic Areas:
Industry:Information Technology & Consulting (Pharmaceutical Services Provider)
Sub-Industry:AI Drug Discovery, Cloud Computing, Quantum Computing, Life Sciences Consulting
SIZE & FINANCIALS
Employees:10000+
Revenue:$62.7B
Founded:1911
Ownership:public
Status:operating
STOCK
Exchange:NYSE
Ticker:IBM
Market Cap:$272.48B
PIPELINE
Stage:N/A - Technology Provider
Lead Drug Stage:N/A - Provides AI/quantum tools to pharma companies
Modalities:mAb (Monoclonal Antibodies), mRNA, Small Molecule, Gene Therapy
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Red Hat (acquired 2019), HashiCorp (acquired 2024), Apptio (acquired 2023), StreamSets and webMethods (from Software AG, acquired 2024), DataStax (acquired 2024)
Key Partnerships:Boehringer Ingelheim: Generative AI and foundation models for therapeutic antibody discovery, Moderna: Quantum computing and generative AI for mRNA drug development, Pfizer: Watson for Drug Discovery in immuno-oncology research (historical), Cleveland Clinic: Discovery Accelerator for quantum computing in drug discovery and antibiotic resistance prediction, MIT: MIT-IBM Watson AI Lab - advanced AI research with applications to biomedicine, STFC Hartree Centre: Quantum computing integration for drug discovery workflows, Meta: AI Alliance for responsible AI development and benchmarking, HCLTech: Generative AI Center of Excellence for watsonx deployment in life sciences
COMPETITION
Position:Leader in AI/Quantum computing for pharma enablement
Competitors:Google DeepMind, Amazon AWS (with AI for drug discovery), Microsoft Azure (with AI services), Recursion Pharmaceuticals, Insilico Medicine, Atomwise, BenevolentAI, NVIDIA +2 more
LEADERSHIP
Key Executives:
Arvind Krishna - Chairman, President, and CEO
James J. Kavanaugh - Senior Vice President and Chief Financial Officer
Rob Thomas - Senior Vice President, Software and Chief Commercial Officer
Sebastian Krause - Senior Vice President and Chief Revenue Officer
Kelly C. Chambliss - Senior Vice President of IBM Consulting, Americas
Anne E. Robinson - Senior Vice President and Chief Legal Officer
Nickle LaMoreaux - Senior Vice President and Chief Human Resources Officer
Mohamad Ali - Senior Vice President, IBM Consulting
Ana Paula Assis - Senior Vice President, EMEA and Growth Markets
Board Members:Frederick H. Waddell (Board Chair), Arvind Krishna (CEO and Board Member), Thomas Buberl (Board Member), Michael Miebach (Board Member), Martha E. Pollack (Board Member)
LINKS
Website:ibm.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with IBM. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.